Survey of amphotericin B susceptibility of Candida clinical isolates determined by Etest

Journal of Microbiology, Immunology and Infection

Volumn 39, Issue 4, 2006, Pages 335-341

  Chiu, Yu Shin ^a,b   Chang, Shan Chwen ^a,c   Hsueh, Po Ren ^a   Wang, Jiun Ling ^a   Sun, Hsin Yun ^a   Chen, Yee Chun ^a,c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b MIN SHENG GENERAL HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Amphotericin B; Candida; Fungal drug resistance; Microbial sensitivity tests

Indexed keywords

AMPHOTERICIN B;

ARTICLE; BLOOD SAMPLING; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA GUILLIERMONDII; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CONTROLLED STUDY; DRUG SENSITIVITY; HEMATOLOGIC MALIGNANCY; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; TEACHING HOSPITAL;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; DRUG RESISTANCE, FUNGAL; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 33750596120     PISSN: 16841182     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Wenzel RP. Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 1995;20:1531-4.
2. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis 1993;167:1247-51.
3. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med 2002;113:480-5.
4. Chen YC, Chang SC, Sun CC, Yang LS, Hsieh WC, Luh KT. Secular trends in the epidemiology of nosocomial fungal infections at a teaching hospital in Taiwan, 1981 to 1993. Infect Control Hosp Epidemiol 1997;18:369-75.
5. Hung CC, Chen YC, Chang SC, Luh KT, Hsieh WC. Nosocomial candidemia in a university hospital in Taiwan. J Formos Med Assoc 1996;95:19-28.
6. Chen YC, Chang SC, Luh KT, Hsieh WC. Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years. J Antimicrob Chemother 2003;52:71-7.
7. Kontoyiannis DP, Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet 2002;359:1135-44.
8. Rex JH, Cooper CR Jr, Merz WG, Galgiani JN, Anaissie EJ. Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob Agents Chemother 1995;39:906-9.
9. Powderly WG, Kobayashi GS, Herzig GP, Medoff G. Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med 1988;84:826-32.
10. Wanger A, Mills K, Nelson PW, Rex JH. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob Agents Chemother 1995;39:2520-2.
11. Abbas J, Bodey GP, Hanna HA, Mardani M, Girgawy E, Abi-Said D, et al. Candida krusei fungemia. An escalating serious infection in immunocompromised patients. Arch Intern Med 2000;160:2659-64.
12. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeast. Approved standard. NCCLS document M27-A. Wayne, Pa: National Committee for Clinical Laboratory Standards Press; 1997.
13. Chen YC, Chang SC, Hsieh WC, Luh KT. In vitro antifungal susceptibilities of Candida species isolated from the blood. Int J Antimicrob Agents 1996;7:217-22.
14. Nguyen MH, Clancy CJ, Yu VL, Yu YC, Morris AJ, Snydman DR, et al. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis 1998;177:425-30.
15. Antoniadou A, Torres HA, Lewis RE, Thornby J, Bodey GP, Tarrand JP, et al. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore) 2003;82:309-21.
16. Warnock DW, Johnson EM, Rogers TR. Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. BSAC Working Party on Antifungal Chemotherapy. J Antimicrob Chemother 1998;42:321-31.
17. Law D, Moore CB, Denning DW. Amphotericin B resistance testing of Candida spp.: a comparison of methods. J Antimicrob Chemother 1997;40:109-12.
18. Warren NG, Hazen KC. Candida, Cryptococcus, and other yeasts of medical importance. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of clinical microbiology. 8th ed. Washington, DC: American Society for Microbiology Press; 2004:1693-711.
19. Clancy CJ, Nguyen MH. Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: results from a multicenter prospective study of candidemia. Antimicrob Agents Chemother 1999;43:1289-90.
20. Wang JL, Chang SC, Hsueh PR, Chen YC. Species distribution and fluconazole susceptibility of Candida clinical isolates in a medical center in 2002. J Microbiol Immunol Infect 2004;37:236-41.
21. Pfaller MA, Messer SA, Bolmstrom A. Evaluation of Etest for determining in vitro susceptibility of yeast isolates to amphotericin B. Diagn Microbiol Infect Dis 1998;32:223-7.
22. Yang YL, Ho YA, Cheng HH, Ho M, Lo HJ. Susceptibilities of Candida species to amphotericin B and fluconazole: the emergence of fluconazole resistance in Candida tropicalis. Infect Control Hosp Epidemiol 2004;25:60-4.
23. Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003;47:3149-54.
24. Lu JJ, Lee SY, Chiueh TS. In vitro antifungal susceptibility testing of Candida blood isolates and evaluation of the E-test method. J Microbiol Immunol Infect 2004;37:335-42.
25. Cheng MF, Yu KW, Tang RB, Fan YH, Yang YL, Hsieh KS, et al. Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999. Diagn Microbiol Infect Dis 2004;48:33-7.
26. Cuenca-Estrella M, Rodriguez D, Almirante B, Morgan J, Planes AM, Almela M, et al; Barcelona Candidemia Project Study Group. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Chemother 2005;55:194-9.
27. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998;11:382-402.
28. Kelly SL, Lamb DC, Kelly DE, Loeffler J, Einsele H. Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients. Lancet 1996;348:1523-4.
29. Fields BT Jr, Bates JH, Abernathy RS. Amphotericin B serum concentrations during therapy. Appl Microbiol 1970;19:955-9.
30. Orozco AS, Higginbotham LM, Hitchcock CA, Parkinson T, Falconer D, Ibrahim AS, et al. Mechanism of fluconazole resistance in Candida krusei. Antimicrob Agents Chemother 1998;42:2645-9.
31. Akova M, Akalin HE, Uzun O, Gur D. Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole. Eur J Clin Microbiol Infect Dis 1991;10:598-9.
32. Hsueh PR, Lau YJ, Chuang YC, Wan JH, Huang WK, Shyr JM, et al. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003. Antimicrob Agents Chemother 2005;49:512-7.
33. Canton E, Peman J, Gobernado M, Viudes A, Espinel-Ingroff A. Patterns of amphotericin B killing kinetics against seven Candida species. Antimicrob Agents Chemother 2004;48:2477-82.
34. Perea S, Patterson TF. Antifungal resistance in pathogenic fungi. Clin Infect Dis 2002;35:1073-80.
35. Dick JD, Merz WG, Saral R. Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob Agents Chemother 1980;18:158-63.
36. Fan-Havard P, Capano D, Smith SM, Mangia A, Eng RH. Development of resistance in Candida isolates from patients receiving prolonged antifungal therapy. Antimicrob Agents Chemother 1991;35:2302-5.
37. Kovacicova G, Hanzen J, Pisarcikova M, Sejnova D, Horn J, Babela R, et al. Nosocomial fungemia due to amphotericin B-resistant Candida spp. in three pediatric patients after previous neurosurgery for brain tumors. J Infect Chemother 2001;7:45-8.